Go Pro
NASDAQ:PMVP

PMV Pharmaceuticals Q4 2024 Earnings Report

PMV Pharmaceuticals logo
$1.20 -0.02 (-1.23%)
Closing price 07/6/2026 04:00 PM Eastern
Extended Trading
$1.25 +0.04 (+3.73%)
As of 07/6/2026 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PMV Pharmaceuticals EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.37
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 3, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

PMV Pharmaceuticals' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

PMV Pharmaceuticals Earnings Headlines

SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.tc pixel
PMV Pharmaceuticals Announces Board Chair Transition
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

View PMV Pharmaceuticals Profile